Compass Pathways Delnica

Compass Pathways EBITDA

EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo) od Compass Pathways (CMPS) na dan 7. avg. 2026 je −179,04 Mio. USD. V prejšnjem letu je EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo) znašal −178,21 Mio. USD — sprememba za 0,47 % (nižje).

EBITDA

−179,04 Mio.USD

YoY

0,47%

Zadnja posodobitev:

EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo) od Compass Pathways je 2026 −179,04 Mio. USD. EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo) od Compass Pathways je bil 2025 −178,21 Mio. USD. Pada za 0,47% nižje v primerjavi s prejšnjim letom.
Access this data via the Eulerpool API

Compass Pathways Analiza delnic

Kaj dela Compass Pathways? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways je eno najbolj priljubljenih podjetij na Eulopoolu.

Pogosto zastavljena vprašanja o delnici Compass Pathways

EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo) podjetja Compass Pathways znaša −179,04 Mio. USD v letu 2026.

EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo) od Compass Pathways se je spremenil z −178,21 Mio. USD na −179,04 Mio. USD, kar predstavlja spremembo za 0,47 %. Vrednost je nižje kot v prejšnjem letu.

Na Eulopoolu najdete celovit zgodovinski razvoj EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo) Compass Pathways od leta 2006 – z letnimi vrednostmi, grafi in podrobno analizo.

EBITDA meri operativno učinkovitost pred vplivom finančne strukture, davčnega okolja in ne-gotovinskih stroškov amortizacije.

EBITDA = EBIT + Amortizacija in deprecijacija

EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo)s USD je ključni dejavnik za vlagatelje. Spremembe te metrike lahko signalizirajo izboljšanje ali poslabšanje temeljnih podatkov, kar neposredno vpliva na ceno delnice. Na Euloolu lahko spremljate EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo)s Compass Pathways v realnem času in zgodovinsko.

Access this data via the Eulerpool API

Izkaz poslovnega izida — Compass Pathways

Vse ključne metrike — Compass Pathways